Phibro Animal Health (NASDAQ:PAHC) Rating Increased to Strong-Buy at StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday.

A number of other brokerages have also issued reports on PAHC. JPMorgan Chase & Co. started coverage on shares of Phibro Animal Health in a research report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 target price on the stock. Bank of America boosted their target price on shares of Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a research report on Friday, August 30th. Finally, Barclays lifted their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Phibro Animal Health presently has an average rating of “Hold” and a consensus price target of $16.50.

Phibro Animal Health Trading Up 0.8 %

Shares of PAHC stock opened at $25.27 on Tuesday. Phibro Animal Health has a 1 year low of $9.49 and a 1 year high of $25.98. The firm’s fifty day simple moving average is $22.57 and its 200 day simple moving average is $19.61. The firm has a market capitalization of $1.02 billion, a P/E ratio of 58.77, a price-to-earnings-growth ratio of 0.66 and a beta of 0.51. The company has a current ratio of 3.23, a quick ratio of 1.69 and a debt-to-equity ratio of 1.81.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. The business had revenue of $273.16 million for the quarter, compared to analyst estimates of $262.44 million. As a group, sell-side analysts predict that Phibro Animal Health will post 1.59 EPS for the current year.

Insiders Place Their Bets

In other news, Director E Thomas Corcoran bought 5,000 shares of the stock in a transaction dated Wednesday, September 4th. The shares were acquired at an average price of $20.02 per share, with a total value of $100,100.00. Following the acquisition, the director now owns 25,000 shares in the company, valued at $500,500. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 50.07% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

A number of hedge funds and other institutional investors have recently bought and sold shares of PAHC. Sofinnova Investments Inc. acquired a new stake in Phibro Animal Health during the 2nd quarter valued at $3,975,000. American Century Companies Inc. increased its holdings in Phibro Animal Health by 119.6% during the 2nd quarter. American Century Companies Inc. now owns 347,191 shares of the company’s stock valued at $5,822,000 after purchasing an additional 189,068 shares in the last quarter. Acadian Asset Management LLC increased its holdings in Phibro Animal Health by 32.8% during the 1st quarter. Acadian Asset Management LLC now owns 675,207 shares of the company’s stock valued at $8,726,000 after purchasing an additional 166,776 shares in the last quarter. Dana Investment Advisors Inc. increased its holdings in Phibro Animal Health by 17.2% during the 2nd quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock valued at $8,619,000 after purchasing an additional 75,546 shares in the last quarter. Finally, Algert Global LLC increased its holdings in Phibro Animal Health by 521.1% during the 3rd quarter. Algert Global LLC now owns 71,335 shares of the company’s stock valued at $1,606,000 after purchasing an additional 59,850 shares in the last quarter. 99.34% of the stock is owned by institutional investors and hedge funds.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.